公开(公告)号：US20240092887A1

公开(公告)日：2024-03-21

申请号：US18364185

申请日：2023-08-02

Applicant: Genentech, Inc.

Inventor： Gerald R. NAKAMURA ,  Dhaya SESHASAYEE ,  Menno VAN LOOKEREN CAMPAGNE ,  Tiffany WONG ,  Jia WU ,  Hongkang XI ,  Jack BEVERS, III ,  Hiu Nam CHAN ,  Laetitia COMPS-AGRAR ,  Racquel CORPUZ

IPC: C07K16/24 ,  A61K39/395 ,  A61K45/06

CPC classification number: C07K16/244 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505

Abstract: The invention provides interleukin-33 (IL-33) antibodies and methods of making and using the same, e.g., for treatment of IL-33 mediated disorders (e.g., ocular disorders such as AMD (e.g., geographic atrophy (GA)).

公开(公告)号：US20150216970A1

公开(公告)日：2015-08-06

申请号：US14333375

申请日：2014-07-16

Applicant: GENENTECH, INC.

Inventor： Jane GROGAN ,  Robert J. JOHNSTON ,  Bryan IRVING ,  Jason HACKNEY ,  Xin YU ,  Dan EATON ,  Kristin BOWLES ,  Laetitia COMPS-AGRAR

IPC: A61K39/395 ,  A61K45/06

CPC classification number: C07K16/2803 ,  A01K67/0276 ,  A01K2217/075 ,  A01K2227/105 ,  A01K2267/0331 ,  A01K2267/0387 ,  A61K39/3955 ,  A61K39/39558 ,  A61K45/06 ,  A61K2039/507 ,  C07K14/70596 ,  C07K16/2818 ,  C07K16/2827 ,  C07K16/3015 ,  C07K16/3023 ,  C07K16/303 ,  C07K16/3038 ,  C07K16/3046 ,  C07K16/3053 ,  C07K16/3061 ,  C07K16/3069 ,  C07K2319/30 ,  Y02A50/466

Abstract: The present invention describes combination treatment comprising a PD-1 axis binding antagonist and an agent that decreases or inhibits TIGIT expression and/or activity and methods for use thereof, including methods of treating conditions where enhanced immunogenicity is desired such as increasing tumor immunogenicity for the treatment of cancer or chronic infection.

Abstract translation: 本发明描述了包含PD-1轴结合拮抗剂和降低或抑制TIGIT表达和/或活性的试剂的组合治疗及其使用方法，包括治疗需要增强免疫原性的病症的方法，例如增加肿瘤免疫原性 治疗癌症或慢性感染。

公开(公告)号：US20170044256A1

公开(公告)日：2017-02-16

申请号：US15239569

申请日：2016-08-17

Applicant: Genentech, Inc.

Inventor： Jane GROGAN ,  Robert J. JOHNSTON ,  Bryan IRVING ,  Jason HACKNEY ,  Xin YU ,  Dan EATON ,  Kristin BOWLES ,  Laetitia COMPS-AGRAR

IPC: C07K16/28 ,  A61K39/395 ,  C07K16/30 ,  A61K45/06

CPC classification number: C07K16/2803 ,  A01K67/0276 ,  A01K2217/075 ,  A01K2227/105 ,  A01K2267/0331 ,  A01K2267/0387 ,  A61K39/3955 ,  A61K39/39558 ,  A61K45/06 ,  A61K2039/507 ,  C07K14/70596 ,  C07K16/2818 ,  C07K16/2827 ,  C07K16/3015 ,  C07K16/3023 ,  C07K16/303 ,  C07K16/3038 ,  C07K16/3046 ,  C07K16/3053 ,  C07K16/3061 ,  C07K16/3069 ,  C07K2319/30 ,  Y02A50/466

Abstract: The present invention describes combination treatment comprising a PD-1 axis binding antagonist and an agent that decreases or inhibits TIGIT expression and/or activity and methods for use thereof, including methods of treating conditions where enhanced immunogenicity is desired such as increasing tumor immunogenicity for the treatment of cancer or chronic infection.

Abstract translation: 本发明描述了包含PD-1轴结合拮抗剂和降低或抑制TIGIT表达和/或活性的试剂的组合治疗及其使用方法，包括治疗需要增强免疫原性的病症的方法，例如增加肿瘤免疫原性 治疗癌症或慢性感染。

公开(公告)号：US20210284725A1

公开(公告)日：2021-09-16

申请号：US17199810

申请日：2021-03-12

Applicant: Genentech, Inc.

Inventor： Gerald R. NAKAMURA ,  Dhaya SESHASAYEE ,  Menno VAN LOOKEREN CAMPAGNE ,  Tiffany WONG ,  Jiansheng WU ,  Hongkang XI ,  Jack BEVERS, III ,  Joyce CHAN ,  Laetitia COMPS-AGRAR ,  Racquel CORPUZ

IPC: C07K16/24 ,  A61K45/06 ,  A61K39/395

Abstract: The invention provides interleukin-33 (IL-33) antibodies and methods of making and using the same, e.g., for treatment of IL-33 mediated disorders (e.g., ocular disorders such as AMD (e.g., geographic atrophy (GA)).

公开(公告)号：US20170037127A1

公开(公告)日：2017-02-09

申请号：US15239524

申请日：2016-08-17

Applicant: Genentech, Inc.

Inventor： Jane GROGAN ,  Robert J. JOHNSTON ,  Bryan IRVING ,  Jason HACKNEY ,  Xin YU ,  Dan EATON ,  Kristin BOWLES ,  Laetitia COMPS-AGRAR

IPC: C07K16/28 ,  A61K45/06 ,  C07K16/30

CPC classification number: C07K16/2803 ,  A01K67/0276 ,  A01K2217/075 ,  A01K2227/105 ,  A01K2267/0331 ,  A01K2267/0387 ,  A61K39/3955 ,  A61K39/39558 ,  A61K45/06 ,  A61K2039/507 ,  C07K14/70596 ,  C07K16/2818 ,  C07K16/2827 ,  C07K16/3015 ,  C07K16/3023 ,  C07K16/303 ,  C07K16/3038 ,  C07K16/3046 ,  C07K16/3053 ,  C07K16/3061 ,  C07K16/3069 ,  C07K2319/30 ,  Y02A50/466

Abstract: The present invention describes combination treatment comprising a PD-1 axis binding antagonist and an agent that decreases or inhibits TIGIT expression and/or activity and methods for use thereof, including methods of treating conditions where enhanced immunogenicity is desired such as increasing tumor immunogenicity for the treatment of cancer or chronic infection.